Albany Molecular Research (AMRI) and Codexis have signed a Smartsourcing partnership for improved process development.
The collaboration, which is scheduled for two years, will focus on integrating the capabilities and technologies of both the companies to increase the value of specific projects by lowering costs, enhancing yields with cleaner processes and/or faster turnaround times.
AMRI chairman, president and CEO Thomas D’Ambra said, "Combining AMRI’s expertise in chemistry, biocatalysis, quality assurance and manufacturing with Codexis’ cutting-edge biocatalysis technology and services, creates a proprietary advantage to our customer’s development projects."
Partners will combine their expertise to find out and implement new manufacturing routes for elected active pharmaceutical ingredients (APIs).
Codexis’ directed evolution technology designed for swift enzyme discovery and optimization, AMRI’s process development and manufacturing technology will be leveraged in the alliance.
Codexis pharmaceuticals SVP Dr. Peter Seufer-Wasserthal said, "Codexis selected AMRI for this collaboration because AMRI understands the opportunity to use biocatalysis for effective and comprehensive route assessment and manufacturing."